FMC · Fmc Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.47B | $4.25B | $4.49B | $5.80B | $5.05B | $4.64B |
| Cost of Revenue | $2.18B | $2.60B | $2.66B | $2.60B | $2.87B | $2.59B |
| Gross Profit | $1.28B | $1.65B | $1.83B | $2.33B | $2.17B | $2.05B |
| R&D | $266.10M | $278.00M | $328.80M | $314.20M | $304.70M | $287.90M |
| SG&A | $684.90M | $644.60M | $734.30M | $775.20M | $714.10M | $729.70M |
| Total Operating Expenses | $5.10B | $3.74B | $3.93B | $4.66B | $3.74B | - |
| D&A | $173.60M | $176.30M | $184.30M | $169.40M | $170.90M | $162.70M |
| Operating Income | ($1.63B) | $506.50M | $555.60M | $1.14B | $1.04B | $902.20M |
| Interest Expense | $239.60M | $235.80M | $237.20M | $151.80M | $131.10M | $151.30M |
| Income Tax | $314.20M | ($150.90M) | ($1.12B) | $145.20M | $91.60M | $150.90M |
| Net Income | ($2.24B) | $341.10M | $1.32B | $736.50M | $736.50M | $551.50M |
| EPS - Basic | ($17.88) | $2.73 | $10.55 | $5.83 | $5.72 | $4.24 |
| EPS - Diluted | ($17.88) | $2.72 | $10.53 | $5.81 | $5.70 | $4.22 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $584.50M | $357.30M | $302.40M | $572.00M | $516.80M | $568.90M |
| Accounts Receivable | $2.06B | $2.90B | $2.70B | $2.87B | $2.58B | $2.33B |
| Inventory | $1.22B | $1.20B | $1.72B | $1.65B | $1.41B | $1.10B |
| Accounts Payable | $771.00M | $768.50M | $602.40M | $1.25B | $1.14B | $946.70M |
| Current Assets | $4.96B | $4.96B | $5.13B | $5.44B | $4.94B | $4.38B |
| Total Assets | $9.69B | $11.65B | $11.93B | $11.17B | $10.58B | $10.19B |
| Current Liabilities | $3.76B | $3.02B | $3.38B | $3.80B | $3.52B | $2.83B |
| Long-term Debt | $2.77B | $3.03B | $3.02B | $2.73B | $2.73B | $2.93B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $2.07B | $4.49B | $4.41B | $3.38B | $3.03B | $2.96B |
| Retained Earnings | $4.17B | $6.64B | $6.59B | $5.56B | $4.99B | $4.51B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($6.20M) | $736.70M | ($300.30M) | $660.00M | $898.60M | $736.80M |
| Investing Cash Flow | ($99.70M) | $263.60M | ($154.40M) | ($266.40M) | ($131.70M) | ($200.40M) |
| Financing Cash Flow | $386.00M | ($870.10M) | $331.50M | ($250.30M) | ($747.90M) | ($250.30M) |
| CapEx | $96.30M | $67.90M | $133.90M | $142.30M | $100.10M | $67.20M |
| Free Cash Flow | ($102.50M) | $668.80M | ($434.20M) | $517.70M | $798.50M | $669.60M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 37.0% | 38.8% | 40.8% | 40.1% | 43.0% | 44.2% |
| Operating margin | -47.0% | 11.9% | 12.4% | 19.7% | 20.7% | 19.4% |
| EBITDA margin | -42.0% | 16.1% | 16.5% | 22.6% | 24.1% | 22.9% |
| Net margin | -64.6% | 8.0% | 29.5% | 12.7% | 14.6% | 11.9% |
| Free cash flow margin | -3.0% | 15.8% | -9.7% | 8.9% | 15.8% | 14.4% |
| FCF / Net income | 0.05 | 1.96 | -0.33 | 0.70 | 1.08 | 1.21 |
| R&D / Revenue | 7.7% | 6.5% | 7.3% | 5.4% | 6.0% | 6.2% |
| SG&A / Revenue | 19.8% | 15.2% | 16.4% | 13.4% | 14.2% | 15.7% |
| Effective tax rate | - | -79.3% | -553.6% | 16.5% | 11.1% | 21.5% |
| Return on assets | -23.1% | 2.9% | 11.1% | 6.6% | 7.0% | 5.4% |
| Return on equity | -108.1% | 7.6% | 30.0% | 21.8% | 24.3% | 18.6% |
| Return on invested capital | -26.6% | 6.7% | 7.5% | 15.6% | 16.1% | 12.0% |
| Liquidity | ||||||
| Current ratio | 1.32 | 1.64 | 1.52 | 1.43 | 1.40 | 1.55 |
| Quick ratio | 1.00 | 1.24 | 1.01 | 1.00 | 1.00 | 1.16 |
| Cash ratio | 0.16 | 0.12 | 0.09 | 0.15 | 0.15 | 0.20 |
| Leverage | ||||||
| Debt / Equity | 1.34 | 0.67 | 0.69 | 0.81 | 0.90 | 0.99 |
| Debt / Assets | 0.29 | 0.26 | 0.25 | 0.24 | 0.26 | 0.29 |
| Debt / EBITDA | - | 4.43 | 4.09 | 2.08 | 2.25 | 2.75 |
| Interest coverage | -6.8x | 2.1x | 2.3x | 7.5x | 8.0x | 6.0x |
| Equity multiplier | 4.68 | 2.60 | 2.70 | 3.31 | 3.49 | 3.44 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.36 | 0.36 | 0.38 | 0.52 | 0.48 | 0.46 |
| Inventory turnover | 1.79 | 2.16 | 1.54 | 1.57 | 2.04 | 2.36 |
| Days sales outstanding | 217d | 250d | 220d | 181d | 187d | 183d |
| Days inventory outstanding | 204d | 169d | 237d | 232d | 179d | 154d |
| Days payable outstanding | 129d | 108d | 83d | 176d | 144d | 133d |
| Cash conversion cycle | 292d | 310d | 374d | 237d | 221d | 204d |
| Valuation | ||||||
| P / E | - | 17.9x | 6.0x | 21.5x | 19.3x | 27.2x |
| P / B | 0.8x | 1.4x | 1.8x | 4.7x | 4.7x | 5.1x |
| P / S | 0.5x | 1.4x | 1.8x | 2.7x | 2.8x | 3.2x |
| EV / EBITDA | - | 12.8x | 14.4x | 13.7x | 13.5x | 16.3x |
| Growth | ||||||
| Revenue growth (YoY) | -18.3% | -5.4% | -22.7% | 15.0% | 8.7% | 0.7% |
| Revenue CAGR (3y) | -15.8% | -5.6% | -1.1% | 8.0% | 2.2% | 17.3% |
| Revenue CAGR (5y) | -5.7% | -1.6% | -1.0% | 15.0% | 9.0% | 7.2% |
| Gross profit growth (YoY) | -22.2% | -9.9% | -21.3% | 7.1% | 5.8% | -1.5% |
| Operating income growth (YoY) | - | -8.8% | -51.4% | 9.5% | 15.8% | 9.8% |
| Net income growth (YoY) | - | -74.2% | 79.4% | 0.0% | 33.5% | 15.5% |
| EPS growth (YoY) | - | -74.2% | 81.2% | 1.9% | 35.1% | 16.6% |
| EPS CAGR (3y) | - | -21.9% | 35.6% | 17.1% | 15.6% | 1.9% |
| EPS CAGR (5y) | - | -5.6% | 23.3% | 7.8% | 29.6% | 2.9% |
| FCF growth (YoY) | - | - | - | -35.2% | 19.3% | 45.0% |
| FCF CAGR (5y) | - | 7.7% | - | 17.7% | 14.5% | - |
| Book value growth (YoY) | -53.8% | 1.7% | 30.6% | 11.4% | 2.4% | 17.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$3.47B totalInsecticides$1.57B · 45.4%
Herbicides$1.25B · 36.0%
Fungicides$362.80M · 10.5%
Plant Health$190.90M · 5.5%
Product And Service Other$94.10M · 2.7%
Geographic
$5.51B totalLatin America$1.35B · 24.5%
BR$1.12B · 20.3%
North America$1.10B · 20.0%
US$923.10M · 16.8%
EMEA$871.50M · 15.8%
Asia$142.30M · 2.6%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Chemicals & Allied Products
Comparing FMC CORP against the 5 most active filers in the same SIC group.
Dividends
$1.32/share trailing 12 months · -43.1% YoY
| Ex-date | Per share |
|---|---|
| Mar 31, 2026 | $0.0800 |
| Dec 31, 2025 | $0.0800 |
| Sep 30, 2025 | $0.5800 |
| Jun 30, 2025 | $0.5800 |
| Mar 31, 2025 | $0.5800 |
| Dec 31, 2024 | $0.5800 |
| Sep 30, 2024 | $0.5800 |
| Jun 28, 2024 | $0.5800 |
| Mar 27, 2024 | $0.5800 |
| Dec 28, 2023 | $0.5800 |
| Sep 28, 2023 | $0.5800 |
| Jun 29, 2023 | $0.5800 |
| Mar 30, 2023 | $0.5800 |
| Dec 29, 2022 | $0.5800 |
| Sep 29, 2022 | $0.5300 |
| Jun 29, 2022 | $0.5300 |
| Mar 30, 2022 | $0.5300 |
| Dec 30, 2021 | $0.5300 |
| Sep 29, 2021 | $0.4800 |
| Jun 29, 2021 | $0.4800 |
| Mar 30, 2021 | $0.4800 |
| Dec 30, 2020 | $0.4800 |
| Sep 29, 2020 | $0.4400 |
| Jun 29, 2020 | $0.4400 |